TY - JOUR
T1 - Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial
AU - Feun, Lynn G.
AU - O'Brien, Christopher
AU - Molina, Enrique
AU - Rodriguez, Miguel
AU - Jeffers, Lenox
AU - Schiff, Eugene R.
AU - Marini, Angela
AU - Savaraj, Niramol
AU - Ardalan, Bach
N1 - Funding Information:
Supported in part by a grant from Roche Laboratories.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.
AB - Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.
KW - 5FUDR
KW - Doxorubicin
KW - Hepatocellular carcinoma
KW - Interferon
UR - http://www.scopus.com/inward/record.url?scp=0037249292&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037249292&partnerID=8YFLogxK
U2 - 10.1007/s00432-002-0398-2
DO - 10.1007/s00432-002-0398-2
M3 - Article
C2 - 12618896
AN - SCOPUS:0037249292
VL - 129
SP - 17
EP - 20
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
SN - 0171-5216
IS - 1
ER -